Press Releases Roche Holding AG BOERSE MUENCHEN

Equities

RHO

CH0012032113

Real-time BOERSE MUENCHEN Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

28/06	Swiss Market Index Closes Little Changed Amid Key European Inflation Data	MT
28/06	Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	15/06	BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk	07/06	BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	29/05	BU
Roche and Hitachi High-Tech extend their long-standing partnership	28/05	AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	21/05	BU
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	16/05	BU
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	19/04	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	17/04	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	15/04	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	25/03	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	12/03	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	26/02	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	19/02	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	16/02	BU
AlzeCure Pharma broadcasts live expert event on Alzheimer's around highly current gamma-secretase modulators	12/02	AQ
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	01/02	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	01/02	BU
Prolight`s CEO to BioStock: "Roche's acquisition highlights interest in Point-of-Care"	29/01	AQ
Reminder, Invitation to Roche's Full Year Results 2023 Presentation	26/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST